These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33152418)

  • 1. Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry.
    Gresele P; Guglielmini G; Del Pinto M; Calabrò P; Pignatelli P; Patti G; Pengo V; Antonucci E; Cirillo P; Fierro T; Palareti G; Marcucci R;
    Int J Cardiol; 2021 Mar; 327():176-182. PubMed ID: 33152418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry.
    Cirillo P; Di Serafino L; Taglialatela V; Calabrò P; Antonucci E; Gresele P; Palareti G; Patti G; Pengo V; Pignatelli P; Marcucci R
    Angiology; 2020 Mar; 71(3):235-241. PubMed ID: 31867981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term prognostic effect of prior cerebrovascular and peripheral artery disease in patients with acute coronary syndrome: Can we do better?
    Cordeiro F; Mateus PS; Ferreira A; Leao S; Moz M; Moreira JI;
    Eur Heart J Acute Cardiovasc Care; 2018 Oct; 7(7):652-660. PubMed ID: 28627932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry.
    Cirillo P; Di Serafino L; Patti G; Antonucci E; Calabrò P; Gresele P; Palareti G; Pengo V; Pignatelli P; Marcucci R
    Angiology; 2019 Mar; 70(3):257-263. PubMed ID: 29969919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry.
    Marcucci R; Patti G; Calabrò P; Gori AM; Grossi G; Cirillo P; Pengo V; Gresele P; Pignatelli P; Antonucci E; di Mario C; Valente S; Palareti G
    PLoS One; 2019; 14(7):e0219676. PubMed ID: 31306454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
    Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
    Franzone A; Piccolo R; Gargiulo G; Ariotti S; Marino M; Santucci A; Baldo A; Magnani G; Moschovitis A; Windecker S; Valgimigli M
    JAMA Cardiol; 2016 Oct; 1(7):795-803. PubMed ID: 27572001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
    Verdoia M; Nardin M; Gioscia R; Negro F; Marcolongo M; Suryapranata H; Kedhi E; De Luca G;
    Vascul Pharmacol; 2020 Sep; 132():106765. PubMed ID: 32681888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
    Rasia M; Solinas E; Marino M; Guastaroba P; Menozzi A; Cattabiani MA; Tadonio I; De Palma R; Vignali L
    J Thromb Thrombolysis; 2017 Nov; 44(4):466-474. PubMed ID: 28994036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry.
    Cesaro A; Gragnano F; Calabrò P; Moscarella E; Santelli F; Fimiani F; Patti G; Cavallari I; Antonucci E; Cirillo P; Pignatelli P; Palareti G; Pelliccia F; Bossone E; Pengo V; Gresele P; Marcucci R;
    Int J Cardiol; 2021 Dec; 345():7-13. PubMed ID: 34695525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
    Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
    Song PS; Hahn JY; Kim DI; Song YB; Choi SH; Choi JH; Ryu DR; Hur SH; Jeong JO; Park HS; Kim HS; Gwon HC
    Eur J Intern Med; 2015 Sep; 26(7):521-7. PubMed ID: 26153337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry.
    Calabrò P; Gragnano F; Di Maio M; Patti G; Antonucci E; Cirillo P; Gresele P; Palareti G; Pengo V; Pignatelli P; Pennacchi M; Granatelli A; De Servi S; De Luca L; Marcucci R;
    Angiology; 2018 Oct; 69(9):795-802. PubMed ID: 29544348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.